Close Menu

NEW YORK – Guardant Health said Thursday that it is collaborating with Radius Health to pursue regulatory approval of its Guardant360 CDx assay as a companion diagnostic for elacestrant (RAD1901), an investigational selective estrogen receptor degrader being studied in the treatment of advanced ER-positive, HER2-negative breast cancers that are resistant to CDK4/6 inhibitors in combination with hormone therapy. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.